• Echo Therapeutics (Franklin, Massachusetts) reported publication of results from three pilot clinical studies of its Symphony Transdermal Continuous Glucose Monitoring (tCGM) system in the Journal of Diabetes Science and Technology. The article highlights that each of the three pilot clinical studies produced positive results supporting the use of Echo's Symphony tCGM System for reliable, non-invasive, real-time continuous glucose monitoring, and its most recently developed skin permeation device, the Prelude SkinPrep System. Echo Therapeutics makes transdermal medical devices and specialty pharmaceuticals.

• Lumedx (Oakland, California) reported the introduction of CardioPACS 5.0, the latest version of its cardiology PACS software. Multi-modality, web-enabled and vendor-neutral, CardioPACS 5.0 is a next-generation PACS solution. With CardioPACS 5.0, physicians can view diagnostic-quality images in real-time from any network-connected PC in any location — the OR, the Cath lab, their own offices, remote outreach or mobile clinics. CardioPACS offers: on-demand workstations wherever your facility requires: anywhere in the hospital and throughout the network; imaging for multiple clinical areas — Cath, Echo, Nuclear, CT MR, PET CT and SPECT — at one workstation; and real-time access to images from any connected location, onsite or off. Lumedx makes cardiovascular imaging and information solutions.

• Masimo (Irvine, California) said that a new clinical study, published in the June issue of the British Journal of Anaesthesia, concluded that under the study protocol Masimo's PVI measurement "can predict fluid responsiveness in mechanically-ventilated patients under general anesthesia." PVI is a new measurement available in the Masimo Rainbow SET technology platform that allows noninvasive, automated, and continuous monitoring of the variation in the pulse oximeter waveform amplitude during respiration. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, and PVI, in addition to oxyhemoglobin, pulse rate, and perfusion index, allowing early detection and treatment of potentially life- threatening conditions. Masimo specializes in pulse oximetry products.

• NewCardio (Santa Clara, California) reported the results of its second external validation study of QTinno (the NCE2 Study). The study was led by an independent industry leading cardiac safety expert with extensive experience in pharmaceutical clinical trials. The NCE2 study evaluated the accuracy, precision and speed of NewCardio's lead product, QTinno, in producing fully automated measurements of drug-induced QT prolongation, a key cardiac safety indicator. QTinno is a software suite that provides automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators. NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead ECG.

• Rosetta Genomics (Jersey City, New Jersey) said that the results of a study conducted by its scientists and collaborators and describing the use of microRNAs in accurately differentiating primary from metastatic tumors of the brain, have been published online in the peer-reviewed journal Brain Pathology. The findings demonstrate microRNAs' potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify primary tumors in patients with brain cancers. Rosetta Genomics specializes in microRNA-based diagnostic and therapeutic products.